California medtech making FDA-approved AI-powered personalised spine surgery technology (aprevo).
| Date | Round | Amount |
|---|---|---|
| Mar 2024 | Series C Carlsmed raised a $52.5M Series C co-led by B Capital and US Venture Partners to commercialise its aprevo personalised spine surgery platform. | $52.5M |
Tap an investor to see what else they have backed.
Data is community-curated and may be incomplete.